OncoMatch/Clinical Trials/NCT07132918
HEARTS Trial for Thoracic Cancers
Is NCT07132918 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for non-small cell lung cancer (stage iii).
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart. The main question it aims to answer is whether MRgART affects the heart differently than LINAC. Participants will: * Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Esophageal Carcinoma
Disease stage
Required: Stage IIB, IIIA, IIIB, IIIC, IV, I, II, III (AJCC 8th edition)
Stage IIB, IIIA, IIIB, IIIC, or IV non-operable non-small cell lung cancer; Limited stage small cell lung cancer; Stage I-III N0-2 disease esophageal/esophagogastric cancer; Stage II or III thymoma/thymic carcinoma
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Wisconsin - Madison · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07132918 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIB or IIIA or IIIB or IIIC or IV or I or II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify